EndMT-derived mesenchymal stem cells: a new therapeutic target to atherosclerosis treatment.

Zhang, Xiaofan; Ren, Zhong; Jiang, Zhisheng

Zhang, Xiaofan; Ren, Zhong; Jiang, Zhisheng.

Zhang X; Institute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan Province, International Joint Laboratory for Arteriosclerotic Disease Research of Hunan Province, Hengyang Medical School, University of South China, Hengyang, 421001, China.
Ren Z; Institute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan Province, International Joint Laboratory for Arteriosclerotic Disease Research of Hunan Province, Hengyang Medical School, University of South China, Hengyang, 421001, China.
Jiang Z; Institute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan Province, International Joint Laboratory for Arteriosclerotic Disease Research of Hunan Province, Hengyang Medical School, University of South China, Hengyang, 421001, China. zsjiang2005@163.com.

Mol Cell Biochem ; 478(4): 755-765, 2023 Apr.

Article en En | MEDLINE | ID: mdl-36083511

Asunto(s)

Aterosclerosis; Células Progenitoras Endoteliales; Trasplante de Células Madre Mesenquimatosas; Células Madre Mesenquimatosas; Placa Aterosclerótica; Humanos; Aterosclerosis/terapia; Aterosclerosis/metabolismo; Placa Aterosclerótica/metabolismo; Diferenciación Celular; Células Madre Mesenquimatosas/metabolismo

Palabras clave

Atherosclerosis; Blood cell; Endothelial-to-mesenchymal transition (EndMT); Haemangioblast; Mesenchymal stem cell (MSC)

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trasplante de Células Madre Mesenquimatosas / Aterosclerosis / Placa Aterosclerótica / Células Madre Mesenquimatosas / Células Progenitoras Endoteliales Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google